Last reviewed · How we verify

Placebo + Letrozole/Anastrozole

Xuanzhu Biopharmaceutical Co., Ltd. · Phase 3 active Small molecule

Placebo + Letrozole/Anastrozole is a Aromatase inhibitor Small molecule drug developed by Xuanzhu Biopharmaceutical Co., Ltd.. It is currently in Phase 3 development for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women.

Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.

Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. Used for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women.

At a glance

Generic namePlacebo + Letrozole/Anastrozole
SponsorXuanzhu Biopharmaceutical Co., Ltd.
Drug classAromatase inhibitor
TargetAromatase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

By inhibiting the aromatase enzyme, these drugs decrease the production of estrogen, which can slow the growth of hormone receptor-positive breast cancer cells. This mechanism is particularly effective in postmenopausal women, as their bodies produce less estrogen naturally.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo + Letrozole/Anastrozole

What is Placebo + Letrozole/Anastrozole?

Placebo + Letrozole/Anastrozole is a Aromatase inhibitor drug developed by Xuanzhu Biopharmaceutical Co., Ltd., indicated for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women.

How does Placebo + Letrozole/Anastrozole work?

Letrozole and Anastrozole are aromatase inhibitors that block the enzyme responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body.

What is Placebo + Letrozole/Anastrozole used for?

Placebo + Letrozole/Anastrozole is indicated for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women.

Who makes Placebo + Letrozole/Anastrozole?

Placebo + Letrozole/Anastrozole is developed by Xuanzhu Biopharmaceutical Co., Ltd. (see full Xuanzhu Biopharmaceutical Co., Ltd. pipeline at /company/xuanzhu-biopharmaceutical-co-ltd).

What drug class is Placebo + Letrozole/Anastrozole in?

Placebo + Letrozole/Anastrozole belongs to the Aromatase inhibitor class. See all Aromatase inhibitor drugs at /class/aromatase-inhibitor.

What development phase is Placebo + Letrozole/Anastrozole in?

Placebo + Letrozole/Anastrozole is in Phase 3.

What are the side effects of Placebo + Letrozole/Anastrozole?

Common side effects of Placebo + Letrozole/Anastrozole include Hot flashes, Vaginal dryness, Musculoskeletal pain, Fatigue, Headache.

What does Placebo + Letrozole/Anastrozole target?

Placebo + Letrozole/Anastrozole targets Aromatase and is a Aromatase inhibitor.

Related